Hans-Christian Kolberg, MD: Real-World Evidence and Biosimilar Trastuzumab
Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, discusses the role of real-world evidence for biosimilar trastuzumab.
Transcript
Real-world data are something that are needed, and actually that is one of the huge problems we have. For companies selling biosimilars, real-world data are after-sales service. It’s very difficult to get funding for that.
We are at the moment planning a study, a real-world study on cardiac safety. We’re trying to predict cardiac safety with early endpoints by drawing blood after 2 cycles of the biosimilar—of antibody—trying to measure in the blood biomarkers that may predict cardiac failure in patients.
This is a classical real-world study, and this is very important because cardiac safety, the cardiac signals in trastuzumab trials, have been decreasing over the years, not because trastuzumab is less cardiotoxic, but because people are more aware of cardiotoxicity, and of course the inclusion/exclusion criteria have been developed and are more strict. So we may ask ourselves, is this really real-world that we’re seeing?
This is why we believe doing a real-world study—and actually, we found a sponsor for that study—it’s very important to include all patients who are, in the real world, candidates for trastuzumab in a safety study, and not only from a clinical registration trial. Of course, inclusion/exclusion criteria are designed so you’re safe for ethical reasons.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
